Sarepta, Prosensa jump after Duchenne forum
Duchenne muscular dystrophy (DMD) companies Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Prosensa Holding N.V. (NASDAQ:RNA) both jumped almost 20% on Thursday on comments and presentations made at the Duchenne Policy Forum. At the forum organized by patient advocacy group Parent Project Muscular Dystrophy, FDA and other stakeholders made presentations on topics including potential biomarkers and surrogate endpoints for DMD.
Sarepta, which closed up $3.30 (19%) to $20.71 on the day, said it was not involved with the forum; the company attributed the Thursday stock moves to "interest in moving forward with therapies for Duchennes." Prosensa Holding N.V. (NASDAQ:RNA) closed up $0.72 (18%) to $4.81. The company did have members present at the forum but declined to comment on the stock jumps. BioCentury was unable to obtain a copy of comments allegedly made at the forum by Janet Woodcock, director of FDA's Center for Drug Evaluation and Research. FDA did not provide a comment in time for publication. ...